FRMD6 and glioblastoma: Moreover, we show for the first time that expression of a constitutively active c-Met, the TPR-Met fusion protein, largely reverses the anti-GBM effect of FRMD6 in vivo, suggesting that FRMD6 functions through inhibiting activity of RKTs especially c-Met.